Evidence map›Paper›PMID 41483307›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Machine learning for automated differentiation of parkinson's disease and its mimics using ¹²³I-mIBG scintigraphy: insights from a multicentre real-world cohort (ITA-mIBG study).

Luca Filippi, Francesco Bianconi, Viviana Frantellizzi, Cristina Ferrari, Andrea Marongiu, Maria Silvia De Feo, Claudia Battisti, Gayane Aghakhanyan, Maria Gazzilli, Nicoletta Urbano and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Luca FilippiDepartment of Biomedicine and Prevention, University of Rome 'Tor Vergata', Via Montpellier, 1, 00133, Rome, Italy. luca.filippi@uniroma2.it.ORCID 0000-0003-4423-5496
Francesco BianconiDepartment of Engineering, Università degli Studi di Perugia, Perugia, Italy.ORCID 0000-0003-3371-1928
Viviana FrantellizziDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Cristina FerrariNuclear Medicine Unit, Interdisciplinary Department of Medicine, University "Aldo Moro", Bari, Italy.
Andrea MarongiuUnit of Nuclear Medicine, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Maria Silvia De FeoDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Claudia BattistiNuclear Medicine Unit, Interdisciplinary Department of Medicine, University "Aldo Moro", Bari, Italy.
Gayane AghakhanyanRegional Center of Nuclear Medicine, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, Italy.
Maria GazzilliNuclear Medicine Unit, Azienda Sanitaria Locale Bari - P.O. Di Venere, Bari, Italy.
Nicoletta UrbanoNuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, Italy.
Susanna NuvoliUnit of Nuclear Medicine, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Duccio VolterraniRegional Center of Nuclear Medicine, Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, Italy.
Mario Luca FravoliniDepartment of Engineering, Università degli Studi di Perugia, Perugia, Italy.
Giuseppe RubiniNuclear Medicine Unit, Interdisciplinary Department of Medicine, University "Aldo Moro", Bari, Italy.
Giuseppe De VincentisDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Angela SpanuUnit of Nuclear Medicine, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Barbara PalumboSection of Nuclear Medicine and Health Physics, Department of Medicine and Surgery, Università degli Studi di Perugia, Perugia, Italy.

Funding

This work was partially supported by funding of the Italian Ministry of Health [Ricerca corrente] This work was partially supported by funding of the Italian Ministry of Health [Ricerca corrente]
6 · The paper itself

Abstract

purposeTo assess machine learning (ML) classifiers trained on harmonised multicentre ¹²³I-mIBG planar scintigraphy for differentiating Parkinson's disease (PD) from non-PD parkinsonian syndromes and to determine whether early imaging alone may ensure accurate discrimination.

methodsThis retrospective study included patients with suspected PD who underwent early (~ 15 min) and delayed (~ 240 min) imaging and received a definitive diagnosis after ≥ 12 months. Harmonised region of interest (ROI) placement and ComBat correction were applied. Early and late heart-to-mediastinum (H/M) ratios and washout rate (WR) were calculated. Differences were tested by Mann-Whitney U test, and cut-points identified by ROC analysis. Logistic regression, Gaussian naïve Bayes, and support vector machine were trained on these features with Z-score normalisation and synthetic minority oversampling technique (SMOTE).

results127 patients were analysed (85 PD, 42 non-PD). Early and late H/M ratios were significantly lower in PD than non-PD (early H/M 1.45 ± 0.20 vs. 1.80 ± 0.20; late H/M 1.33 ± 0.22 vs. 1.68 ± 0.21; both p < 0.001). WR was modestly higher in PD (8.74 ± 5.76% vs. 6.49 ± 6.19%, p = 0.024). Optimal cut-points for PD were: early H/M ≤ 1.62 (accuracy 80.3%, sensitivity 83.3%, specificity 78.8%, and AUC 0.878), late H/M ≤ 1.52 (83.5%, 83.3%, 83.5% and 0.866) and WR ≥ 6.03% (70.1%, 70.6%, 69.0% and 0.645). ML achieved mean accuracy 78.9-80.7%, sensitivity 81.9-84.0%, specificity 68.6-78.0%, and AUC 0.850-0.875.

conclusionClassifiers trained on ¹²³I-mIBG semi-quantitative indices accurately distinguished PD from non-PD. Early H/M ratio alone provided excellent discrimination, supporting early-imaging; prospective validation is warranted.

Indexed as

3-IodobenzylguanidineMachine LearningParkinson DiseaseAgedAutomationCohort StudiesDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRadionuclide ImagingRetrospective Studies3-Iodobenzylguanidine¹²³I-mIBG scintigraphyArtificial intelligenceCardiac sympathetic denervationComBat harmonisationDiagnostic accuracyHeart-to-mediastinum ratioMachine learningMulticentre harmonisationParkinson’s disease

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.